NCT03994302View on ClinicalTrials.gov

Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)

CompletedOBSERVATIONAL
Enrollment

2,700

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

June 30, 2021

Study Completion Date

April 8, 2023

Conditions
Antiphospholipid SyndromeImmune DiseaseAdverse Drug EventDrug Toxicity
Interventions
DRUG

Drug inducing antiphospholipid syndrome

Drugs susceptible to induce immune toxicities such as antiphospholipid syndrome

Trial Locations (1)

75013

AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, Paris

All Listed Sponsors
lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT03994302 - Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX) | Biotech Hunter | Biotech Hunter